Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BI's Spiriva HandiHaler Joins GSK's Advair Diskus In COPD Exacerbations Reduction Claim

This article was originally published in The Pink Sheet Daily

Executive Summary

The steroid-free, long-acting anticholinergic gains another selling point as others ready drugs for the $7 billion to $8 billion COPD market.
Advertisement

Related Content

Almirall Signs Up Forest For Once-Daily LABA
Safety Meta-Analysis Trumped By Long, Large Trial At Spiriva Advisory Panel
BI's Spiriva Gets Advisory Panel Nod For COPD Exacerbations Despite Statistical Issues
BI's Spiriva Gets Advisory Panel Nod For COPD Exacerbations Despite Statistical Issues
Forest Acquires U.S. Rights To Nycomed's Oral COPD Drug Daxas
AstraZeneca’s Symbicort On Advair’s Heels With COPD Approval

Topics

Advertisement
UsernamePublicRestriction

Register

PS068898

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel